bioAffinity Technologies Q2 2026: Going Concern Warning, Nasdaq Delisting Notice, Cash Runway Through August
BIAF is trading near its 52-week low of $0.507 (0.6% above the low).
Summary
bioAffinity Technologies' Q2 2026 filing discloses a going concern warning, a Nasdaq delisting notice, and a cash runway that ends this month. CyPath Lung revenue is growing but losses are accelerating, and the company urgently needs new financing.
Key Events · Earnings and Guidance · BIAF
-
Going Concern Warning
Management concludes substantial doubt about the company's ability to continue as a going concern. Cash of $2.4M at June 30, 2026, is only sufficient to fund operations through August 2026.
-
Nasdaq Delisting Notice
Received July 30, 2026, for failing the $1 minimum bid price rule. The company has requested a hearing appeal, staying any delisting action pending the panel's decision.
-
Q2 2026 Financial Results
Net loss of $3.4M for Q2, $7.0M for H1 2026. Revenue of $1.5M for Q2, up 19% YoY, driven by CyPath Lung growth, but operating expenses rose 28% to $4.8M.
-
CyPath Lung Revenue Growth
CyPath Lung testing revenue increased 159% to $835K in H1 2026 vs $323K in H1 2025. Unit sales grew 216% in Q2, with 1,100 tests delivered in H1.
Analysis · BIAF · Industrial Applications And Services
bioAffinity Technologies' Q2 2026 10-Q reveals a critical liquidity crisis. With only $2.4 million in cash at June 30 and a burn rate that depletes funds by August 2026, management has issued a going concern warning. The company also received a Nasdaq delisting notice for failing the $1 minimum bid price rule, adding listing risk to the financial distress. While CyPath Lung revenue grew 159% year-over-year to $835,000 in the first half, it is nowhere near enough to offset a $7 million net loss. The company raised $3.2 million in June but needs immediate additional capital to survive. The stock trades near its 52-week low of $0.51, reflecting the market's assessment of these existential risks.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 43.8% of the 290 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIAF was trading at $0.51 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.51 to $13.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.